Nelarabin
Klinički podaci | |
---|---|
Prodajno ime | Arranon, Arranon (GlaxoSmithKline), Atriance |
Drugs.com | Monografija |
Način primene | Intravenozno |
Farmakokinetički podaci | |
Poluvreme eliminacije | 30 minuta - 3 h |
Izlučivanje | Renalno |
Identifikatori | |
CAS broj | 121032-29-9 Y |
ATC kod | L01BB07 (WHO) |
PubChem | CID 3011155 |
DrugBank | DB01280 Y |
ChemSpider | 2280207 Y |
ChEMBL | CHEMBL1201112 Y |
Hemijski podaci | |
Formula | C11H15N5O5 |
Molarna masa | 297,267 |
SMILES
| |
InChI
| |
Fizički podaci | |
Tačka topljenja | 209—217 °C (408—423 °F) |
Nelarabin je organsko jedinjenje, koje sadrži 11 atoma ugljenika i ima molekulsku masu od 297,267 Da.[1][2][3][4][5][6][7]
Osobine
Osobina | Vrednost |
---|---|
Broj akceptora vodonika | 9 |
Broj donora vodonika | 4 |
Broj rotacionih veza | 3 |
Particioni koeficijent[8] (ALogP) | -1,4 |
Rastvorljivost[9] (logS, log(mol/L)) | -0,4 |
Polarna površina[10] (PSA, Å2) | 148,8 |
Reference
- ^ Buie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007 Sep;29(9):1887-99. PMID 18035189
- ^ DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. PMID 19825456
- ^ Roecker AM, Allison JC, Kisor DF: Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol. 2006 Aug;2(4):441-8. PMID 16922610
- ^ Sanford M, Lyseng-Williamson KA: Nelarabine. Drugs. 2008;68(4):439-47. PMID 18318562
- ^ Reilly KM, Kisor DF: Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28. PMID 20616909
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
- Nelarabine
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |